Concepts (62)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Iron Overload | 1 | 2025 | 18 | 0.930 |
Why?
|
| Transfusion Reaction | 1 | 2025 | 42 | 0.930 |
Why?
|
| Cancer Survivors | 2 | 2026 | 283 | 0.870 |
Why?
|
| Erythrocyte Transfusion | 1 | 2025 | 146 | 0.840 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2021 | 5 | 0.670 |
Why?
|
| Denosumab | 1 | 2021 | 13 | 0.670 |
Why?
|
| Bone Density Conservation Agents | 1 | 2021 | 56 | 0.640 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 475 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1272 | 0.410 |
Why?
|
| Neoplasms | 2 | 2026 | 3016 | 0.400 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1545 | 0.330 |
Why?
|
| Hemochromatosis | 1 | 2025 | 44 | 0.230 |
Why?
|
| Ferritins | 1 | 2025 | 104 | 0.230 |
Why?
|
| Aftercare | 1 | 2026 | 157 | 0.210 |
Why?
|
| Iron | 1 | 2025 | 304 | 0.190 |
Why?
|
| Mycoses | 1 | 2021 | 110 | 0.160 |
Why?
|
| Caregivers | 1 | 2026 | 598 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2026 | 722 | 0.150 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2019 | 51 | 0.140 |
Why?
|
| Prevalence | 1 | 2025 | 2701 | 0.140 |
Why?
|
| Liver | 1 | 2025 | 1796 | 0.140 |
Why?
|
| Adolescent | 4 | 2026 | 20987 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 124 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 315 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2019 | 294 | 0.130 |
Why?
|
| Child, Preschool | 4 | 2026 | 15110 | 0.110 |
Why?
|
| Neuroblastoma | 1 | 2019 | 546 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 3763 | 0.100 |
Why?
|
| Infant | 2 | 2025 | 13352 | 0.090 |
Why?
|
| Male | 6 | 2026 | 64957 | 0.090 |
Why?
|
| Child | 4 | 2026 | 26341 | 0.090 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2011 | 18 | 0.090 |
Why?
|
| Tretinoin | 1 | 2011 | 95 | 0.090 |
Why?
|
| Prognosis | 1 | 2021 | 4886 | 0.090 |
Why?
|
| Young Adult | 1 | 2025 | 10103 | 0.080 |
Why?
|
| Proteinuria | 1 | 2011 | 109 | 0.080 |
Why?
|
| Adult | 2 | 2026 | 31282 | 0.070 |
Why?
|
| Humans | 7 | 2026 | 131163 | 0.060 |
Why?
|
| Female | 4 | 2026 | 70963 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1826 | 0.040 |
Why?
|
| Dactinomycin | 1 | 2019 | 47 | 0.040 |
Why?
|
| Foot Diseases | 1 | 2019 | 20 | 0.040 |
Why?
|
| Thoracic Neoplasms | 1 | 2019 | 36 | 0.040 |
Why?
|
| Thigh | 1 | 2019 | 50 | 0.040 |
Why?
|
| Extremities | 1 | 2019 | 73 | 0.040 |
Why?
|
| Thoracic Wall | 1 | 2019 | 40 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 292 | 0.040 |
Why?
|
| Vincristine | 1 | 2019 | 187 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 306 | 0.040 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2019 | 147 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 387 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 428 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 236 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 2019 | 255 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2026 | 5196 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2019 | 8635 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1216 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1680 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2019 | 872 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2021 | 17753 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1336 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 705 | 0.010 |
Why?
|